Serge Saxonov - 04 Jan 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Executive Officer, Director
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol: TXG
Transactions as of: 04 Jan 2022
Net transactions value: -$2,085,159
Form type: 4
Filing time: 06 Jan 2022, 17:55:29 UTC
Previous filing: 30 Dec 2021
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Options Exercise	$34,865	+3,037	+0.33%	$11.48	937,255	04 Jan 2022	Direct	F1
transaction	TXG	Class A Common Stock	Sale	$138,864	-1,000	-0.11%	$138.86	936,255	04 Jan 2022	Direct	F1, F2
transaction	TXG	Class A Common Stock	Sale	$433,444	-3,100	-0.33%	$139.82	933,155	04 Jan 2022	Direct	F1, F3
transaction	TXG	Class A Common Stock	Sale	$756,663	-5,368	-0.58%	$140.96	927,787	04 Jan 2022	Direct	F1, F4
transaction	TXG	Class A Common Stock	Sale	$415,517	-2,932	-0.32%	$141.72	924,855	04 Jan 2022	Direct	F1, F5
transaction	TXG	Class A Common Stock	Sale	$100,179	-700	-0.08%	$143.11	924,155	04 Jan 2022	Direct	F1, F6
transaction	TXG	Class A Common Stock	Sale	$202,695	-1,400	-0.15%	$144.78	922,755	04 Jan 2022	Direct	F1, F7
transaction	TXG	Class A Common Stock	Sale	$72,663	-500	-0.05%	$145.33	922,255	04 Jan 2022	Direct	F1, F8
holding	TXG	Class A Common Stock						4,138	04 Jan 2022	See footnote	F9
holding	TXG	Class A Common Stock						89,960	04 Jan 2022	See footnote	F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (right to buy)	Options Exercise	$0	-3,037	-6.2%	$0.000000	45,559	04 Jan 2022	Class A Common Stock	3,037	$11.48	Direct	F1, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2	This transaction was executed in multiple trades at prices ranging from $138.29 to $139.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3	This transaction was executed in multiple trades at prices ranging from $139.33 to $140.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4	This transaction was executed in multiple trades at prices ranging from $140.38 to $141.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5	This transaction was executed in multiple trades at prices ranging from $141.38 to $142.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6	This transaction was executed in multiple trades at prices ranging from $142.99 to $143.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7	This transaction was executed in multiple trades at prices ranging from $144.185 to $145.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8	This transaction was executed in multiple trades at prices ranging from $145.19 to $145.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F9	The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F10	The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F11	This option, originally for 145,786 shares, of which 100,227 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.